Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models.
Mazahreh R, Mason ML, Gosink JJ, Olson DJ, Thurman R, Hale C, Westendorf L, Pires TA, Leiske CI, Carlson M, Nguyen LT, Cochran JH, Okeley NM, Yumul R, Jin S, Stone IJ, Sahetya D, Nesterova A, Allred S, Hensley KM, Hu R, Lawrence R, Lewis TS, Sandall S. Mazahreh R, et al. Among authors: okeley nm. Mol Cancer Ther. 2023 Apr 3;22(4):421-434. doi: 10.1158/1535-7163.MCT-22-0401. Mol Cancer Ther. 2023. PMID: 36800443 Free PMC article. Clinical Trial.
Anti-CD30 diabody-drug conjugates with potent antitumor activity.
Kim KM, McDonagh CF, Westendorf L, Brown LL, Sussman D, Feist T, Lyon R, Alley SC, Okeley NM, Zhang X, Thompson MC, Stone I, Gerber HP, Carter PJ. Kim KM, et al. Among authors: okeley nm. Mol Cancer Ther. 2008 Aug;7(8):2486-97. doi: 10.1158/1535-7163.MCT-08-0388. Mol Cancer Ther. 2008. PMID: 18723494
Development of Novel Antibody-Camptothecin Conjugates.
Lyski RD, Bou LB, Lau UY, Meyer DW, Cochran JH, Okeley NM, Emmerton KK, Zapata F, Simmons JK, Trueblood ES, Ortiz DJ, Zaval MC, Snead KM, Jin S, Farr LM, Ryan MC, Senter PD, Jeffrey SC. Lyski RD, et al. Among authors: okeley nm. Mol Cancer Ther. 2021 Feb;20(2):329-339. doi: 10.1158/1535-7163.MCT-20-0526. Epub 2020 Dec 3. Mol Cancer Ther. 2021. PMID: 33273058
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.
Gerber HP, Kung-Sutherland M, Stone I, Morris-Tilden C, Miyamoto J, McCormick R, Alley SC, Okeley N, Hayes B, Hernandez-Ilizaliturri FJ, McDonagh CF, Carter PJ, Benjamin D, Grewal IS. Gerber HP, et al. Blood. 2009 Apr 30;113(18):4352-61. doi: 10.1182/blood-2008-09-179143. Epub 2009 Jan 15. Blood. 2009. PMID: 19147785 Free article.
A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.
Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, Hunter JH, Leiske CI, Miyamoto JB, Nicholas ND, Okeley NM, Sanderson RJ, Stone IJ, Zeng W, Gregson SJ, Masterson L, Tiberghien AC, Howard PW, Thurston DE, Law CL, Senter PD. Jeffrey SC, et al. Among authors: okeley nm. Bioconjug Chem. 2013 Jul 17;24(7):1256-63. doi: 10.1021/bc400217g. Epub 2013 Jun 28. Bioconjug Chem. 2013. PMID: 23808985
The pharmacologic basis for antibody-auristatin conjugate activity.
Alley SC, Zhang X, Okeley NM, Anderson M, Law CL, Senter PD, Benjamin DR. Alley SC, et al. Among authors: okeley nm. J Pharmacol Exp Ther. 2009 Sep;330(3):932-8. doi: 10.1124/jpet.109.155549. Epub 2009 Jun 4. J Pharmacol Exp Ther. 2009. PMID: 19498104
28 results